Fujimi, Japan

Tsuneo Okutomi

This inventor holds 2 USPTO granted patents. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 1976.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Fujimi, JA (1976)
  • Tokyo, JA (1976)

Company Filing History:


Years Active: 1976

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tsuneo Okutomi: Innovator in Pharmaceutical Advancements

Introduction

Tsuneo Okutomi is a notable inventor based in Fujimi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of arteriosclerosis and the development of novel antibiotics. With a total of 2 patents, his work has the potential to impact both human and animal health.

Latest Patents

Okutomi's latest patents include a pharmaceutical composition and method for treating arteriosclerosis. This composition features an ascochlorin derivative and a pharmaceutically acceptable carrier, aimed at addressing arteriosclerosis in mammals and poultry. Additionally, he has developed an antibiotic known as ascofuranone, which exhibits hypotensive and hypolipidemic activities. This antibiotic is produced from a microorganism of Ascochyta viciae Libert through aerobic culturing, showcasing innovative processes for its production and use.

Career Highlights

Throughout his career, Okutomi has been associated with Chugai Seiyaku Kabushiki Kaisha, a prominent pharmaceutical company. His work there has allowed him to focus on groundbreaking research and development in the pharmaceutical sector.

Collaborations

Okutomi has collaborated with esteemed colleagues such as Tomoyoshi Hosokawa and Hiroshi Sasaki. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Tsuneo Okutomi's contributions to pharmaceutical science, particularly through his patents, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and antibiotic development.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…